Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
about
Improving clinical outcomes for naltrexone as a management of problem alcohol useRelapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption.Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Rapid opiate detoxification and antagonist induction under general anaesthesia or intravenous sedation is humane, sometimes essential and should always be an option. Three illustrative case reports involving diabetes and epilepsy and a review of theAssessing the usefulness of health data linkage in obtaining adverse event data in a randomised controlled trial of oral and implant naltrexone in the treatment of heroin dependence.Clinical safety of 1500 mg oral naltrexone overdose.Pharmacological enhancement of naltrexone treatment for opioid dependence: a reviewNanoscale effects of ethanol and naltrexone on protein organization in the plasma membrane studied by photoactivated localization microscopy (PALM).Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not availableBuprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependenceDesign of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).Maintenance medication for opiate addiction: the foundation of recovery.Long-acting injectable naltrexone for the management of patients with opioid dependence.Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management.Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.Open label trial of naltrexone implants: measuring blood serum levels of naltrexoneSeeking prescription opioids from physicians for nonmedical use among people who inject drugs in a Canadian setting.Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.Long-acting Preparations in Substance Abuse Management: A Review and Update.A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.Substance abuse/dependence treatment: a European perspective.Antagonist Models for Relapse Prevention and Reducing HIV Risk.Update on pharmacotherapy for treatment of opioid use disorder.Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series.Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance.Opioid Use in the Twenty First Century: Similarities and Differences Across National Borders.Pharmacologically assisted treatment of opioid-dependent youth.A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.Sustained opioid antagonism modulates striatal sensitivity to baby schema in opioid use disorder.Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.
P2860
Q27021406-FFC3C46A-7AF3-4B07-B5EB-1BBF6ADACD12Q30252443-6330FBF6-8379-4A89-AECA-FFB65DCBD082Q33556479-FAD702D5-8E66-4DFA-8B91-33013AD5152AQ33582025-705875A6-2912-4BBB-A41E-9BD26D542B76Q33747985-F70B36A1-DE42-4B8B-ABDF-7AEC2571B1DFQ33783250-6D60EA43-0225-40F3-8F70-DAB3F74663B8Q33870389-94A8B743-F493-4184-9C7D-914BDB3CC9C7Q34277168-984964BE-BE8A-4A44-9DA6-999E6CF09FD7Q34371727-2DB233D4-15D1-4BAE-B417-327F66BA4231Q34513344-F44D5C34-234A-43B4-A41E-CE867760F9DDQ34526419-9F6A317F-E16A-4340-946E-D8A2EB9C811AQ35084340-56FC2A08-D263-4164-A6AA-6DCED8A234AEQ35087610-7CCAE8B0-900A-42CE-B8D4-760F036B1AD7Q35090939-9ABF271D-4768-455C-9B2D-90ABD4FF7E0BQ35178521-61903A88-12F5-4DC9-A97F-BA8D5A53AE76Q35228546-3FF4E0FE-0CA0-4C0C-BBD5-46292A97D4BCQ35566908-BAF5E9E8-B486-4E8E-9363-105950C6CB00Q35670689-0FAAE9D1-C760-48FE-A577-624CC915B7C3Q35827908-17964886-0306-4587-BBE1-AA5065F756B0Q36001217-D0246BEA-2CE4-453E-BD3B-5F8974B9005BQ36138164-DDC641E0-9D0F-4D6D-87DE-3D94012A8B27Q36139018-85D1F011-D951-4639-87B7-8133509D4410Q36300075-5E67D0BE-9789-474E-B60D-2E21232964C1Q36734579-F3033A3F-1A60-4BE9-8D24-6078F9594CB7Q36870420-ADA25D56-D725-4760-B15B-0D014E368E6CQ37097438-8B1DD574-6147-4CC4-8CC6-DDAD134F85FBQ37638805-D135EB7A-3190-4789-BF67-E0E520D900DFQ37873579-5CB095CE-9FBF-48F5-823F-8CF760A9830EQ38119942-42F89644-60D0-4729-88C8-4AD2C57A849DQ38168314-8E15DBF8-6404-4D38-8D13-1722378FCAF9Q38207160-77C59828-DD4A-4E01-B951-2020FDAF9B07Q38382530-DA2305FB-9C79-4808-95E4-E831947674ABQ38979423-6CFE9F81-D74A-4F49-8F15-370B1C04E74DQ39616233-F1D13C8A-4587-440D-9815-727D57D6348BQ39886583-AD5FBCB5-F44B-4D81-989F-02DCE4A5F752Q42389337-B90B1444-8600-4E3F-AE6C-ECA297E6022AQ44340554-006FB7DC-F96E-49B2-AE19-E0EF478C7DB6Q44345882-D92376CF-2AB3-49E7-9144-6B53012F016CQ44351026-4F32A298-89BD-4B5D-B0B9-F49239C28EA2Q45089599-E346D509-732E-4B61-922D-CEDE8217E67C
P2860
Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Improving clinical outcomes in ...... of oral or implant naltrexone.
@ast
Improving clinical outcomes in ...... of oral or implant naltrexone.
@en
type
label
Improving clinical outcomes in ...... of oral or implant naltrexone.
@ast
Improving clinical outcomes in ...... of oral or implant naltrexone.
@en
prefLabel
Improving clinical outcomes in ...... of oral or implant naltrexone.
@ast
Improving clinical outcomes in ...... of oral or implant naltrexone.
@en
P2093
P1433
P1476
Improving clinical outcomes in ...... of oral or implant naltrexone.
@en
P2093
Diane Arnold-Reed
Gary K Hulse
Noella Morris
P304
P356
10.1001/ARCHGENPSYCHIATRY.2009.130
P407
P577
2009-10-01T00:00:00Z